Tuberculosis subunit vaccines: from basic science to clinical testing

More than 80 years after the introduction of Bacillus Calmette–GuÉrin, the first tuberculosis vaccine, new vaccines for tuberculosis are finally in clinical trials. The selection of antigens on which new subunit vaccines are based represent the first fulfilment of the promise of proteomics and �genomics, and the delivery systems for these antigens are likewise the first fruits of the improved understanding of how the host immune system recognizes pathogens. However, clinical trials are still at Phase I and there remain formidable obstacles to the registration of the first new TB vaccines. Here the authors review the vaccines in clinical trials and discuss the different approaches they take to stimulating immunity to Mycobacterium tuberculosis infection, focusing on recombinant subunit vaccines. The challenges that confront these approaches and how they are being addressed are then discussed.

[1]  P. Andersen,et al.  Tuberculosis vaccine development. , 2002, Current opinion in pulmonary medicine.

[2]  R. Rappuoli,et al.  Mucosal Administration of Ag85B-ESAT-6 Protects against Infection with Mycobacterium tuberculosis and Boosts Prior Bacillus Calmette-Guérin Immunity1 , 2006, The Journal of Immunology.

[3]  P. Aaby,et al.  Bacillus Calmette-Guérin vaccination and infant mortality , 2006, Expert review of vaccines.

[4]  P. E. M. Fine,et al.  Variation in protection by BCG: implications of and for heterologous immunity , 1995, The Lancet.

[5]  T. Ottenhoff,et al.  Recognition of Stage-Specific Mycobacterial Antigens Differentiates between Acute and Latent Infections with Mycobacterium tuberculosis , 2006, Clinical and Vaccine Immunology.

[6]  S. Reed,et al.  The Protective Effect of the Mycobacterium bovis BCG Vaccine Is Increased by Coadministration with the Mycobacterium tuberculosis 72-Kilodalton Fusion Polyprotein Mtb72F in M. tuberculosis-Infected Guinea Pigs , 2004, Infection and Immunity.

[7]  J. Sterne,et al.  Does the efficacy of BCG decline with time since vaccination? , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  M. Horwitz,et al.  A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. , 2006, Vaccine.

[9]  M. Havenga,et al.  Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. , 2006, The Journal of general virology.

[10]  S. Reed,et al.  Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, Mtb72F, Delivered as Naked DNA or Recombinant Protein1 , 2004, The Journal of Immunology.

[11]  J. Deeks,et al.  Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study , 2005, The Lancet.

[12]  S. Kaufmann,et al.  Cell-Mediated Immunity Induced by Recombinant Mycobacterium bovis Bacille Calmette-Guérin Strains Against an Intracellular Bacterial Pathogen: Importance of Antigen Secretion or Membrane-Targeted Antigen Display as Lipoprotein for Vaccine Efficacy1 , 2002, The Journal of Immunology.

[13]  J. Gómez-Reino,et al.  Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. , 2007, Arthritis and rheumatism.

[14]  D. Collins,et al.  Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. , 2002, Vaccine.

[15]  G. Bothamley.  BCG and protection against Mycobacterium tuberculosis infection , 2006, The Lancet.

[16]  H. McShane,et al.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans , 2004, Nature Medicine.

[17]  Z. Xing,et al.  Single Mucosal, but Not Parenteral, Immunization with Recombinant Adenoviral-Based Vaccine Provides Potent Protection from Pulmonary Tuberculosis1 , 2004, The Journal of Immunology.

[18]  B. Moss,et al.  Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination , 1988, Journal of virology.

[19]  H. Vordermeier,et al.  Association of Tuberculin-Boosted Antibody Responses with Pathology and Cell-Mediated Immunity in Cattle Vaccinated with Mycobacterium bovis BCG and Infected with M. bovis , 2004, Infection and Immunity.

[20]  R. Rappuoli,et al.  Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines , 2003, Expert review of vaccines.

[21]  M. Horwitz,et al.  A New Vaccine against Tuberculosis Affords Greater Survival after Challenge than the Current Vaccine in the Guinea Pig Model of Pulmonary Tuberculosis , 2003, Infection and Immunity.

[22]  J. T. Ulrich,et al.  Monophosphoryl Lipid A as an Adjuvant , 1995 .

[23]  K. Mulholland.  Evaluation of vaccines to prevent childhood pneumonia: lessons relevant to planning tuberculosis vaccine trials. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Pai,et al.  False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[25]  S. Kaufmann,et al.  Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. , 2004, The Journal of infectious diseases.

[26]  N. Guérin,et al.  Efficacy of BCG vaccination of the newborn: evaluation by a follow-up study of contacts in Bangui. , 1995, International journal of epidemiology.

[27]  S. Kostense,et al.  Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.

[28]  I. Orme,et al.  Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. , 2006, Vaccine.

[29]  P. Andersen.  Vaccine strategies against latent tuberculosis infection. , 2007, Trends in microbiology.

[30]  S. Kaufmann,et al.  Cytolytic T-cell responses to human dendritic cells and macrophages infected with Mycobacterium bovis BCG and recombinant BCG secreting listeriolysin. , 1999, Microbes and infection.

[31]  I. Orme,et al.  Effective Preexposure Tuberculosis Vaccines Fail To Protect When They Are Given in an Immunotherapeutic Mode , 2000, Infection and Immunity.

[32]  J. Dietrich,et al.  Synergistic Effect of Bacillus Calmette Guerin and a Tuberculosis Subunit Vaccine in Cationic Liposomes: Increased Immunogenicity and Protection1 , 2007, The Journal of Immunology.

[33]  P. Andersen,et al.  Oral Vaccination with Subunit Vaccines Protects Animals against Aerosol Infection with Mycobacterium tuberculosis , 2002, Infection and Immunity.

[34]  D. Webster,et al.  Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. , 2006, Vaccine.

[35]  Alan D. Roberts,et al.  Lack of Protection in Mice and Necrotizing Bronchointerstitial Pneumonia with Bronchiolitis in Guinea Pigs Immunized with Vaccines Directed against the hsp60 Molecule ofMycobacterium tuberculosis , 2000, Infection and Immunity.

[36]  I. Orme,et al.  Pulmonary Necrosis Resulting from DNA Vaccination against Tuberculosis , 2003, Infection and Immunity.

[37]  R. Koch.  The Etiology of Tuberculosis , 1982 .

[38]  E. Ziv,et al.  Potential Public Health Impact of New Tuberculosis Vaccines , 2004, Emerging infectious diseases.

[39]  M. Chakraborty,et al.  Recurrent Japanese encephalitis epidemics in West Bengal. , 1980 .

[40]  P. Andersen.  The T cell response to secreted antigens of Mycobacterium tuberculosis. , 1994, Immunobiology.

[41]  D. Snider.  Ethical issues in tuberculosis vaccine trials. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  K. Moelling,et al.  Therapy of tuberculosis in mice by DNA vaccination , 1999, Nature.

[43]  E. Bamgboye,et al.  Does the protective effect of neonatal BCG correlate with vaccine-induced tuberculin reaction? , 1995, American journal of respiratory and critical care medicine.

[44]  H. Vordermeier,et al.  Correlation of ESAT-6-Specific Gamma Interferon Production with Pathology in Cattle following Mycobacterium bovis BCG Vaccination against Experimental Bovine Tuberculosis , 2002, Infection and Immunity.

[45]  G. Rook,et al.  The Koch phenomenon and the immunopathology of tuberculosis. , 1996, Current topics in microbiology and immunology.

[46]  D. Mitchison,et al.  Effect of vaccines in a murine model of dormant tuberculosis. , 1994, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[47]  P. Andersen,et al.  T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis , 1991, Infection and immunity.

[48]  R. Adegbola,et al.  Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design. , 2006, The Lancet. Infectious diseases.

[49]  Kim A. Hatch,et al.  Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. , 2005, Tuberculosis.

[50]  G. Bancroft,et al.  Characterization of Auxotrophic Mutants ofMycobacterium tuberculosis and Their Potential as Vaccine Candidates , 2001, Infection and Immunity.

[51]  C. Dye,et al.  Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness , 2006, The Lancet.

[52]  R. G. Hewinson,et al.  Evaluation of adjuvants for protein vaccines against tuberculosis in guinea pigs. , 2003, Vaccine.

[53]  J. Dietrich,et al.  Prospects for a novel vaccine against tuberculosis. , 2006, Veterinary microbiology.

[54]  W. Schmidt,et al.  Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines. , 2002, Vaccine.

[55]  P. Andersen,et al.  Combination of the Cationic Surfactant Dimethyl Dioctadecyl Ammonium Bromide and Synthetic Mycobacterial Cord Factor as an Efficient Adjuvant for Tuberculosis Subunit Vaccines , 2004, Infection and Immunity.

[56]  G. Baily.  Tuberculosis prevention Trial, Madras. , 1980, The Indian journal of medical research.

[57]  H. McShane,et al.  Translational Mini‐Review Series on Vaccines:
Development and evaluation of improved vaccines against tuberculosis , 2007, Clinical and experimental immunology.

[58]  C S Berkey,et al.  The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. , 1995, Pediatrics.

[59]  H. McShane,et al.  Recombinant Modified Vaccinia Virus Ankara Administration and Boosting with a Bacille Calmette-Guérin Vaccine Using Mucosal of Mycobacterium tuberculosis Efficacy Against Enhanced Immunogenicity and Protective , 2003 .

[60]  C S Berkey,et al.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. , 1994, JAMA.

[61]  I. Orme.  Beyond BCG: the potential for a more effective TB vaccine. , 1999, Molecular medicine today.

[62]  G. Kaplan,et al.  Evaluation of the Mtb72F Polyprotein Vaccine in a Rabbit Model of Tuberculous Meningitis , 2006, Infection and Immunity.

[63]  R. Appelberg,et al.  Failure of the Mycobacterium bovis BCG Vaccine: Some Species of Environmental Mycobacteria Block Multiplication of BCG and Induction of Protective Immunity to Tuberculosis , 2002, Infection and Immunity.

[64]  H. McShane,et al.  Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis , 2001, Infection and Immunity.

[65]  A. Thomas,et al.  Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. , 2005, Vaccine.

[66]  S. Kaufmann,et al.  Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. , 2006, Immunity.

[67]  T. Ottenhoff,et al.  Lack of Immune Responses to Mycobacterium tuberculosis DosR Regulon Proteins following Mycobacterium bovis BCG Vaccination , 2007, Infection and Immunity.

[68]  C. Staib,et al.  Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? , 2004, Current Opinion in Biotechnology.

[69]  T. Eguale,et al.  Immune Responses to the Mycobacterium tuberculosis-Specific Antigen ESAT-6 Signal Subclinical Infection among Contacts of Tuberculosis Patients , 2002, Journal of Clinical Microbiology.

[70]  G. Comstock,et al.  Tuberculosis studies in Muscogee County, Georgia. Twenty-year evaluation of a community trial of BCG vaccination. , 1976, Public health reports.

[71]  S. Morris,et al.  DNA Immunization in a Mouse Model of Latent Tuberculosis: Effect of DNA Vaccination on Reactivation of Disease and on Reinfection with a Secondary Challenge , 2002, Infection and Immunity.

[72]  L. Moulton,et al.  Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. , 2004, JAMA.

[73]  E. Agger,et al.  Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. , 2006, Vaccine.

[74]  M. Pai,et al.  The prognosis of latent tuberculosis: can disease be predicted? , 2007, Trends in molecular medicine.

[75]  R. Koch.  Classics in infectious diseases. The etiology of tuberculosis: Robert Koch. Berlin, Germany 1882. , 1982, Reviews of infectious diseases.

[76]  P. D. Hart,et al.  BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. , 1977, British medical journal.